Indian J Pharm Close
 

Figure 2: 5,5'-dimethoxylariciresinol-4'-O-β-D-glucoside (DMAG)-mediated cell apoptosis in K562 and K562/DOX cells. (a) K562 cells were treated with 0.15 μM of doxorubicin in the presence or absence of 1.0 μM of DMAG or 1.0 μM of verapamil for 24 h and 48 h, and then mean fluorescence intensity (MFI) of propidium iodide (PI) in K562 cells were detected by Array Scan VTIHCS600 High-Contents. (b) K562/DOX cells were treated with 15.0 μM of doxorubicin in the presence or absence of 1.0 μM of DMAG or 1.0 μM of verapamil for 24 h and 48 h and then MFI of PI in K562/DOX cells were detected by Arrary Scan VTIHCS600 High-Contents. *Represents P < 0.01 compared with DOX group. *Represents P < 0.05 compared with DOX + verapamil group

Figure 2: 5,5'-dimethoxylariciresinol-4'-O-β-D-glucoside (DMAG)-mediated cell apoptosis in K562 and K562/DOX cells. (a) K562 cells were treated with 0.15 μM of doxorubicin in the presence or absence of 1.0 μM of DMAG or 1.0 μM of verapamil for 24 h and 48 h, and then mean fluorescence intensity (MFI) of propidium iodide (PI) in K562 cells were detected by Array Scan VTIHCS600 High-Contents. (b) K562/DOX cells were treated with 15.0 μM of doxorubicin in the presence or absence of 1.0 μM of DMAG or 1.0 μM of verapamil for 24 h and 48 h and then MFI of PI in K562/DOX cells were detected by Arrary Scan VTIHCS600 High-Contents. *Represents P < 0.01 compared with DOX group. *Represents P < 0.05 compared with DOX + verapamil group